INKT

AGENUS INC

Known title: 10% OwnerCIK: 0001098972

AGENUS INC's purchase track record

How the stock did after each of AGENUS INC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
6
of 6 since October 19, 2021
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-23.4%
3 months: -8.8%
Beat the S&P 500
0%
median -37.1% vs. index
PurchaseStockAmount3 months6 months
10/12/2023INKT$25K-14.0%-10.5%
10/4/2023INKT$16K-3.5%-15.3%
8/24/2023INKT$326K-34.6%-40.6%
5/11/2023INKT$33K+18.5%-31.5%
5/3/2023INKT$293K+48.7%-12.8%
10/19/2021INKT$16.80M-73.6%-80.6%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative. MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.

this person other insiders at INKT

Transaction History

INKT▲ Buy$472
INKT▲ Buy$21K
INKT▲ Buy$3K
INKT▲ Buy$16K
INKT▲ Buy$45K
INKT▲ Buy$19K
INKT▲ Buy$263K
INKT▲ Buy$33K
INKT▲ Buy$33K
INKT▲ Buy$95K
INKT▲ Buy$250
INKT▲ Buy$26K
INKT▲ Buy$139K
INKT▼ Sell$0
INKT▲ Buy$16.8M
INKT▼ Sell—

We use analytics to understand how market-wall is used. No personal data is sold.